389633-40-3

Upstream product

• 108-24-7 acetic anhydride 
• 389633-39-0 α-(1R,5R,8R)-3,3-dimethyl-6-phenyl-6-(2'-propenyl)-8-(tert-butyldiphenylsilyloxymethyl)-2,4,7-trioxabicyclo[3.3.0]octane 
• 389633-46-9 [(3aR,4S,6R,6aR)-6-(tert-Butyl-diphenyl-silanyloxymethyl)-2,2-dimethyl-4-phenyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl]-acetaldehyde 
• 500229-14-1 (3aR,6R,6aR)-6-Hydroxymethyl-2,2-dimethyl-4-phenyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-ol 
• 141979-56-8 1,5-O-diacetyl-2,3-O-isopropylidene-D-ribofuranoside 
• 174590-90-0 5-O-(tert-butyldiphenylsilyl)-2,3-O-isopropylidene-1-phenyl-D-ribofuranose 
• 32257-17-3 5-Acetyl-2,3-O-isopropyliden-D-ribonolactone 
• 67814-68-0 2,3-O-isopropylidene-D-ribofuranose 

Downstream Products

• 660410-93-5 (1'S,3'R,4'R,5'R,7'R)-N⁴-benzoyl-1-{4'-acetoxy-1'-phenyl-3'-(tert-butyldiphenylsilyloxymethyl)-2',6'-dioxabicyclo[3.3.0]oct-7'-yl}cytosine 
• 660410-94-6 (1'S,3'R,4'R,5'R,7'S)-N⁴-benzoyl-1-{4'-acetoxy-1'-phenyl-3'-(tert-butyldiphenylsilyloxymethyl)-2',6'-dioxabicyclo[3.3.0]oct-7'-yl}cytosine 
• 881423-90-1 1-{(1S,3R,4R,5R,7S)-4-acetoxy-3-[(tert-butyldiphenylsilyloxy)methyl]-1-phenyl-2,6-dioxabicyclo[3.3.0]octan-7-yl}-N⁴-benzoyl-5-fluorocytosine 
• 1195199-11-1 (1'S,3'R,4'R,5'R,7'R)-N₁-benzoyl-2-{4'-acetoxy-1'-phenyl-3'-(t-butyldiphenylsilyloxymethyl)-2',6'-dioxabicyclo[3.3.0]oct-7'-yl}-4-methyl-3-pyrazolin-5-one 
• 1195199-14-4 (1'S,3'R,4'R,5'R,7'S)-N₁-benzoyl-2-{4'-acetoxy-1'-phenyl-3'-(t-butyldiphenylsilyloxymethyl)-2',6'-dioxabicyclo[3.3.0]oct-7'-yl}-4-methyl-3-pyrazolin-5-one 
• 1195199-17-7 (1'S,3'R,4'R,5'R,7'R)-N₂-benzoyl-1-{4'-acetoxy-1'-phenyl-3'-(t-butyldiphenylsilyloxymethyl)-2',6'-dioxabicyclo[3.3.0]oct-7'-yl}-4-methyl-3-pyrazolin-5-one 
• 1195199-21-3 (1'S,3'R,4'R,5'R,7'S)-N₂-benzoyl-1-{4'-acetoxy-1'-phenyl-3'-(t-butyldiphenylsilyloxymethyl)-2',6'-dioxabicyclo[3.3.0]oct-7'-yl}-4-methyl-3-pyrazolin-5-one 

Relevant academic research and scientific papers

Selective Formation of Stable Triplexes Including a TA or a CG Interrupting Site with New Bicyclic Nucleoside Analogues (WNA)

Triplex-forming oligonucleotides (TFOs) are potential DNA-targeting molecules and would become powerful tools for genomic research. As the stabilization of the TFO is partially provided by hydrogen bonds to purine bases, the most stable triplexes form wit

W-shape nucleic acid (WNA) for selective formation of non-natural anti-parallel triplex including a TA interrupting site

Novel nucleoside analogs have been designed for selective formation of anti-parallel triplexes including a TA or a CG interrupting site. The new compounds are constructed of a W-shape bicyclic nucleic acid (WNA) bearing an aromatic ring as a stacking motif and a guanine for the formation of Hoogesteen hydrogen bonds, and are expected to effect triplex stabilization by both stacking and complementary hydrogen bonds. Purine-rich triplex-forming oligodeoxynucleotide (TFO) incorporating the new analog, WNA-7βG, formed a stable triplex with high selectivity to the TA site.